Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. / Guttman, M; Léger, G; Reches, A; Evans, A; Kuwabara, H; Cedarbaum, J M; Gjedde, A.

In: Movement Disorders, Vol. 8, No. 3, 1993, p. 298-304.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Guttman, M, Léger, G, Reches, A, Evans, A, Kuwabara, H, Cedarbaum, JM & Gjedde, A 1993, 'Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.', Movement Disorders, vol. 8, no. 3, pp. 298-304. https://doi.org/10.1002/mds.870080308

APA

Guttman, M., Léger, G., Reches, A., Evans, A., Kuwabara, H., Cedarbaum, J. M., & Gjedde, A. (1993). Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Movement Disorders, 8(3), 298-304. https://doi.org/10.1002/mds.870080308

Vancouver

Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM et al. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. Movement Disorders. 1993;8(3):298-304. https://doi.org/10.1002/mds.870080308

Author

Guttman, M ; Léger, G ; Reches, A ; Evans, A ; Kuwabara, H ; Cedarbaum, J M ; Gjedde, A. / Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa. In: Movement Disorders. 1993 ; Vol. 8, No. 3. pp. 298-304.

Bibtex

@article{162bade0b31511debc73000ea68e967b,
title = "Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.",
abstract = "L-Dopa is metabolized to 3-O-methyldopa (3OMD) by catechol-O-methyltransferase (COMT). This reduces the amount of L-dopa available for entry into brain. We studied the effect of OR-611, a new COMT inhibitor, on plasma and brain 6-[18F]-fluoro-L-dopa (6FD) metabolism in cynomolgus monkeys with positron emission tomography (PET). OR-611 pretreatment substantially reduced plasma 6FD metabolism to 3-O-methylfluorodopa (3OMFD). PET measurements of striatal 6FD concentrations showed an average 2.3-fold increase following OR-611 pretreatment, compared to the same animals in the control state. OR-611 inhibits plasma metabolism of 6FD and increases brain uptake of this L-dopa analog. OR-611 appears to be a promising agent as an adjunct to L-dopa for the treatment of patients with Parkinson's disease.",
author = "M Guttman and G L{\'e}ger and A Reches and A Evans and H Kuwabara and Cedarbaum, {J M} and A Gjedde",
year = "1993",
doi = "10.1002/mds.870080308",
language = "English",
volume = "8",
pages = "298--304",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "JohnWiley & Sons, Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.

AU - Guttman, M

AU - Léger, G

AU - Reches, A

AU - Evans, A

AU - Kuwabara, H

AU - Cedarbaum, J M

AU - Gjedde, A

PY - 1993

Y1 - 1993

N2 - L-Dopa is metabolized to 3-O-methyldopa (3OMD) by catechol-O-methyltransferase (COMT). This reduces the amount of L-dopa available for entry into brain. We studied the effect of OR-611, a new COMT inhibitor, on plasma and brain 6-[18F]-fluoro-L-dopa (6FD) metabolism in cynomolgus monkeys with positron emission tomography (PET). OR-611 pretreatment substantially reduced plasma 6FD metabolism to 3-O-methylfluorodopa (3OMFD). PET measurements of striatal 6FD concentrations showed an average 2.3-fold increase following OR-611 pretreatment, compared to the same animals in the control state. OR-611 inhibits plasma metabolism of 6FD and increases brain uptake of this L-dopa analog. OR-611 appears to be a promising agent as an adjunct to L-dopa for the treatment of patients with Parkinson's disease.

AB - L-Dopa is metabolized to 3-O-methyldopa (3OMD) by catechol-O-methyltransferase (COMT). This reduces the amount of L-dopa available for entry into brain. We studied the effect of OR-611, a new COMT inhibitor, on plasma and brain 6-[18F]-fluoro-L-dopa (6FD) metabolism in cynomolgus monkeys with positron emission tomography (PET). OR-611 pretreatment substantially reduced plasma 6FD metabolism to 3-O-methylfluorodopa (3OMFD). PET measurements of striatal 6FD concentrations showed an average 2.3-fold increase following OR-611 pretreatment, compared to the same animals in the control state. OR-611 inhibits plasma metabolism of 6FD and increases brain uptake of this L-dopa analog. OR-611 appears to be a promising agent as an adjunct to L-dopa for the treatment of patients with Parkinson's disease.

U2 - 10.1002/mds.870080308

DO - 10.1002/mds.870080308

M3 - Journal article

C2 - 8341294

VL - 8

SP - 298

EP - 304

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 3

ER -

ID: 14944407